Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.37 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27469197 | 0.89 | KDM4E (0.48) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL14783984 | 0.84 | MCL1 (0.42) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL16277579 | 0.83 | KEAP1 (0.41) | KDM4EKEAP1NOTUMCES2CES1 | |
| SCHEMBL27303784 | 0.83 | SMN1; SMN2 (0.40) | KDM4EMEN1KMT2ACES2CES1 | |
| SCHEMBL5857864 | 0.83 | CES2 (0.48) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL29657075 | 0.83 | CES2 (0.48) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL23302962 | 0.81 | HMGB1 (0.58) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL18186580 | 0.81 | HSD17B1 (0.46) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL286599 | 0.79 | KDM4E (0.41) | KDM4EMEN1KMT2ATDP1KEAP1 | |
| SCHEMBL15636696 | 0.79 | KDM4E (0.66) | KDM4EMEN1KMT2ATDP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180332-B1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10221170-B2 | Difluoropyrrolidines as orexin receptor modulators | EOLAS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170226103-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008115281-A2 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
| CN-100384836-C | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| CN-1426405-A | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221170-B2 | Difluoropyrrolidines as orexin receptor modulators | HCRTR2, OPRD1, HCRTR1 | KDM4E 1535/4885MEN1 2757/4885KMT2A 1821/4885 |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | KDM4E 3380/4885MEN1 2745/4885KMT2A 3573/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | KDM4E 3921/4885MEN1 3919/4885KMT2A 4574/4885 |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | KDM4E 3380/4885MEN1 2745/4885KMT2A 3573/4885 |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | KDM4E 3380/4885MEN1 2745/4885KMT2A 3573/4885 |
| US-20170226103-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, OPRD1, HCRTR1 | KDM4E 1535/4885MEN1 2757/4885KMT2A 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.